This overexpression proved to be of critical clinical significance, where zolbetuximab, an IgG1 monoclonal antibody, could bind to claudin-18.2 and induce gastric cancer cell death via antibody-dependent and complement-dependent cytotoxicity [33]. This evidence concerns the gene CLDN18 and gastric cancer.